Cadrenal Therapeutics, Inc. (CVKD) Balance Sheet
CVKD balance sheet, 2025
December 31, 2025 · U.S. dollars$4.3M assets = $1.6M liabilities + $2.7M equity
Both columns are drawn to the same scale: what CVKD owns equals what it owes plus shareholders’ equity. Hover a block for its value.
CVKD financial health
Descriptive bands, not a rating. Fiscal 2025.
CVKD balance sheet trends, 2022–2025
| Metric | Trend | Then | Latest | Change |
|---|---|---|---|---|
| Total assets | $778,1742022 | $4.3M2025 | +77.2%/yr | |
| Total liabilities | $6.3M2022 | $1.6M2025 | −36.9%/yr | |
| Shareholders’ equity | −$5.6M2022 | $2.7M2025 | — | |
| Cash & short-term investments | $32,5862022 | $4.0M2025 | +397.3%/yr | |
| Total debt | $640,7062022 | $21,3502023 | −96.7%/yr | |
| Net cash (debt) | −$608,1202022 | $8.4M2023 | +$9.0M | |
| Working capital | −$606,8812022 | $2.7M2025 | +$3.3M | |
| Book value per share | −$7.162022 | $1.372025 | — | |
| Current ratio | 0.552022 | 2.722025 | +2.17 | |
| Shares outstanding | 776K2022 | 2.0M2025 | +37.0%/yr |
Change is the average annual growth (CAGR) or the difference between the first and latest year.
CVKD assets
CVKD liabilities and equity
CVKD debt vs cash
Debt includes short- and long-term borrowings and, where reported, lease obligations.
CVKD balance sheet
| 2025 | 2024 | 2023 | 2022 | |
|---|---|---|---|---|
| Assets | ||||
| Cash & short-term investments | $4.0M | $10.0M | $8.4M | $32,586 |
| Cash & equivalents | $4.0M | $10.0M | $8.4M | $32,586 |
| Receivables | $5,096 | $38,153 | $37,248 | $0 |
| Inventory | $0 | $0 | $0 | $0 |
| Other current assets | $306,482 | $56,702 | $52,425 | $695,010 |
| Total current assets | $4.3M | $10.1M | $8.5M | $727,596 |
| Property, plant & equipment (net) | $5,174 | $6,944 | $23,285 | $44,591 |
| Goodwill & intangible assets | $0 | $0 | $0 | $0 |
| Long-term investments | $0 | $0 | $0 | $0 |
| Other non-current assets | $2,167 | $3,792 | $3,792 | $5,987 |
| Total assets | $4.3M | $10.1M | $8.5M | $778,174 |
| Liabilities | ||||
| Accounts payable | $650,663 | $1.5M | $167,319 | $404,897 |
| Short-term debt | — | — | $21,350 | $66,016 |
| Deferred revenue | — | — | $532,706 | — |
| Total current liabilities | $1.6M | $2.7M | $826,875 | $1.3M |
| Long-term debt | $0 | $0 | $0 | $553,340 |
| Lease obligations | — | $0 | $21,350 | $43,638 |
| Other long-term liabilities | $0 | $0 | $0 | $4.4M |
| Total liabilities | $1.6M | $2.7M | $826,875 | $6.3M |
| Shareholders' equity | ||||
| Common stock & paid-in capital | $2,338 | $1,782 | $13,022 | $8,194 |
| Retained earnings (deficit) | −$39.0M | −$25.7M | −$15.1M | −$6.7M |
| Total shareholders' equity | $2.7M | $7.4M | $7.7M | −$5.6M |
| Key figures | ||||
| Total debt | — | — | $21,350 | $640,706 |
| Net cash (debt) | — | — | $8.4M | −$608,120 |
| Working capital | $2.7M | $7.4M | $7.7M | −$606,881 |
| Tangible book value | $2.7M | $7.4M | $7.7M | −$5.6M |
| Book value per share | $1.37 | $6.10 | $8.86 | −$7.16 |
| Shares outstanding | 2.0M | 1.2M | 868K | 776K |
| Current ratio | 2.72 | 3.77 | 10.27 | 0.55 |
| Quick ratio | 2.53 | 3.75 | 10.21 | 0.02 |
| Debt / equity | — | — | 0.00 | — |
| Equity / assets | 63.3% | 73.5% | 90.3% | −713.4% |
| Jun '26 | Mar '26 | Dec '25 | Sep '25 | Jun '25 | Mar '25 | Dec '24 | Sep '24 | Jun '24 | Mar '24 | Dec '23 | Sep '23 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Assets | ||||||||||||
| Cash & short-term investments | $2.4M | $2.3M | $4.0M | $3.9M | $5.6M | $7.3M | $10.0M | $4.4M | $5.0M | $6.6M | $8.4M | $9.1M |
| Cash & equivalents | $2.4M | $2.3M | $4.0M | $3.9M | $5.6M | $7.3M | $10.0M | $4.4M | $5.0M | $6.6M | $8.4M | $9.1M |
| Receivables | $2.7M | $5,466 | $5,096 | $12,791 | $19,039 | $24,664 | $38,153 | $0 | $0 | $0 | $37,248 | $0 |
| Inventory | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 |
| Other current assets | $505,779 | $541,678 | $306,482 | $206,853 | $382,218 | $584,056 | $56,702 | $308,590 | $406,330 | $461,611 | $52,425 | $168,602 |
| Total current assets | $5.6M | $2.9M | $4.3M | $4.1M | $6.0M | $7.9M | $10.1M | $4.7M | $5.4M | $7.0M | $8.5M | $9.3M |
| Property, plant & equipment (net) | $2,675 | $4,619 | $5,174 | $5,729 | $4,277 | $4,678 | $6,944 | $3,011 | $9,875 | $16,610 | $23,285 | $29,779 |
| Goodwill & intangible assets | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 |
| Long-term investments | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 |
| Other non-current assets | $2,167 | $2,167 | $2,167 | $2,167 | $2,167 | $3,792 | $3,792 | $3,792 | $3,792 | $3,792 | $3,792 | $3,792 |
| Total assets | $5.6M | $2.9M | $4.3M | $4.1M | $6.0M | $8.0M | $10.1M | $4.7M | $5.5M | $7.0M | $8.5M | $9.3M |
| Liabilities | ||||||||||||
| Accounts payable | $871,913 | $824,809 | $650,663 | $614,127 | $895,609 | $1.3M | $1.5M | $496,823 | $759,518 | $400,373 | $167,319 | $141,658 |
| Short-term debt | — | — | — | — | — | — | — | $2,232 | $8,796 | $15,167 | $21,350 | $24,991 |
| Total current liabilities | $1.5M | $1.1M | $1.6M | $1.4M | $1.7M | $1.8M | $2.7M | $1.3M | $1.5M | $856,315 | $826,875 | $563,566 |
| Long-term debt | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 |
| Lease obligations | — | — | — | — | — | — | $0 | $2,232 | $8,796 | $15,167 | $21,350 | $27,223 |
| Other long-term liabilities | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $2,232 |
| Total liabilities | $1.5M | $1.1M | $1.6M | $1.4M | $1.7M | $1.8M | $2.7M | $1.3M | $1.5M | $856,315 | $826,875 | $565,798 |
| Shareholders' equity | ||||||||||||
| Common stock & paid-in capital | $3,098 | $2,507 | $2,338 | $2,059 | $2,006 | $1,909 | $1,782 | $1,234 | $16,008 | $16,008 | $13,022 | $13,022 |
| Retained earnings (deficit) | −$44.8M | −$41.5M | −$39.0M | −$35.9M | −$33.2M | −$29.6M | −$25.7M | −$21.5M | −$19.1M | −$16.7M | −$15.1M | −$13.9M |
| Total shareholders' equity | $4.1M | $1.8M | $2.7M | $2.7M | $4.3M | $6.1M | $7.4M | $3.4M | $4.0M | $6.2M | $7.7M | $8.7M |
| Key figures | ||||||||||||
| Total debt | — | — | — | — | — | — | — | $2,232 | $8,796 | $15,167 | $21,350 | $27,223 |
| Net cash (debt) | — | — | — | — | — | — | — | $4.4M | $5.0M | $6.6M | $8.4M | $9.1M |
| Working capital | $4.1M | $1.8M | $2.7M | $2.7M | $4.3M | $6.1M | $7.4M | $3.4M | $4.0M | $6.2M | $7.7M | $8.7M |
| Tangible book value | $4.1M | $1.8M | $2.7M | $2.7M | $4.3M | $6.1M | $7.4M | $3.4M | $4.0M | $6.2M | $7.7M | $8.7M |
| Book value per share | $1.40 | $0.75 | $1.37 | $1.34 | $2.19 | $3.31 | $4.88 | $3.09 | $3.74 | $5.79 | $8.86 | $10.07 |
| Shares outstanding | 2.9M | 2.4M | 2.0M | 2.0M | 2.0M | 1.8M | 1.5M | 1.1M | 1.1M | 1.1M | 868K | 868K |
| Current ratio | 3.73 | 2.68 | 2.72 | 3.02 | 3.56 | 4.32 | 3.77 | 3.69 | 3.72 | 8.21 | 10.27 | 16.46 |
| Quick ratio | 3.39 | 2.17 | 2.53 | 2.86 | 3.33 | 4.00 | 3.75 | 3.44 | 3.44 | 7.67 | 10.21 | 16.16 |
| Debt / equity | — | — | — | — | — | — | — | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Equity / assets | 73.2% | 62.8% | 63.3% | 66.9% | 71.9% | 76.9% | 73.5% | 72.9% | 73.2% | 87.9% | 90.3% | 93.9% |
Quarterly columns are labeled by the month the quarter ended. Figures in U.S. dollars as reported (latest annual report filed March 31, 2026); data from EODHD.
CVKD financial position
At the end of fiscal 2025 (December 31, 2025), Cadrenal Therapeutics had total assets of $4.3 million (down 57.3% from a year earlier), total liabilities of $1.6 million and shareholders' equity of $2.7 million. Its current ratio was 2.72. In the latest quarter (ended June 30, 2026) total assets were $5.6 million and equity $4.1 million.
Related: CVKD income statement, CVKD cash flow statement, CVKD key metrics. See the CVKD stock overview for the latest quote and news.
CVKD balance sheet FAQ
What are Cadrenal Therapeutics's total assets?
Cadrenal Therapeutics reported total assets of $4.3 million at the end of fiscal 2025 (December 31, 2025), compared with $10.1 million a year earlier.
How much cash does Cadrenal Therapeutics have?
Cadrenal Therapeutics held $4.0 million in cash and short-term investments at the end of fiscal 2025.
What is Cadrenal Therapeutics's book value?
Cadrenal Therapeutics's shareholders' equity (book value) was $2.7 million at the end of fiscal 2025, or $1.37 per share.
What is Cadrenal Therapeutics's current ratio?
Cadrenal Therapeutics had current assets of $4.3 million and current liabilities of $1.6 million, a current ratio of 2.72 (it can cover its short-term obligations).